Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
45
CLDI Quote, Financials, Valuation and Earnings
Last price:
$0.61
Seasonality move
:
-36.42%
Day range:
$0.60 - $0.71
52-week range:
$0.20 - $3.89
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.91x
Volume:
4.4M
Avg. volume:
28.4M
1-year change:
-66.37%
Market cap:
$20.1M
Revenue:
--
EPS (TTM):
-$15.03
Analysts' Opinion
-
Consensus RatingCalidi Biotherapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $6.25, Calidi Biotherapeutics has an estimated upside of 1481.78% from its current price of $0.63.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.50 representing 100% downside risk from its current price of $0.63.
Fair Value
-
According to the consensus of 2 analysts, Calidi Biotherapeutics has 1481.78% upside to fair value with a price target of $6.25 per share.
CLDI vs. S&P 500
-
Over the past 5 trading days, Calidi Biotherapeutics has underperformed the S&P 500 by -9.74% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Calidi Biotherapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Calidi Biotherapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Calidi Biotherapeutics reported revenues of --.
Earnings Growth
-
Calidi Biotherapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Calidi Biotherapeutics reported earnings per share of -$0.18.
Enterprise value:
9.7M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.42x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$19.4M | -$28.1M | -$19.9M | -$6.8M | -$5M | |
| EBITDA | -$22.3M | -$27.4M | -$17.7M | -$6.6M | -$4.6M | |
| Diluted EPS | -$6.42 | -$9.24 | -$15.03 | -$2.03 | -$0.18 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | $1.9M | $11.5M | |
| Total Assets | -- | -- | -- | $7.4M | $15.1M | |
| Current Liabilities | -- | -- | -- | $15M | $5.4M | |
| Total Liabilities | -- | -- | -- | $22M | $7.8M | |
| Total Equity | -- | -- | -- | -$14.6M | $7.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -$27.7M | -$23M | -$3.8M | -$7.1M | |
| Cash From Investing | -- | -$346K | -$18K | -$5K | -$7K | |
| Cash From Financing | -- | $28.3M | $32.5M | $3M | $8.1M | |
| Free Cash Flow | -- | -$28.2M | -$23M | -$3.8M | -$7.1M | |
CLDI
Sector
Market Cap
$20.1M
$34.4M
Price % of 52-Week High
16.25%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-66.37%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.60
200-day SMA
Sell
Level
$0.96
Bollinger Bands (100)
Buy
Level
0.31 - 0.73
Chaikin Money Flow
Sell
Level
-436.1M
20-day SMA
Buy
Level
$0.39
Relative Strength Index (RSI14)
Buy
Level
59.74
ADX Line
Buy
Level
43.66
Williams %R
Neutral
Level
-69.2621
50-day SMA
Buy
Level
$0.39
MACD (12, 26)
Buy
Level
0.08
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
823.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
Stock Forecast FAQ
In the current month, CLDI has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CLDI average analyst price target in the past 3 months is $6.25.
-
Where Will Calidi Biotherapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Calidi Biotherapeutics share price will rise to $6.25 per share over the next 12 months.
-
What Do Analysts Say About Calidi Biotherapeutics?
Analysts are divided on their view about Calidi Biotherapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Calidi Biotherapeutics is a Sell and believe this share price will drop from its current level to $2.50.
-
What Is Calidi Biotherapeutics's Price Target?
The price target for Calidi Biotherapeutics over the next 1-year time period is forecast to be $6.25 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CLDI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Calidi Biotherapeutics is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CLDI?
You can purchase shares of Calidi Biotherapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Calidi Biotherapeutics shares.
-
What Is The Calidi Biotherapeutics Share Price Today?
Calidi Biotherapeutics was last trading at $0.61 per share. This represents the most recent stock quote for Calidi Biotherapeutics. Yesterday, Calidi Biotherapeutics closed at $0.63 per share.
-
How To Buy Calidi Biotherapeutics Stock Online?
In order to purchase Calidi Biotherapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
